{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:04:51Z","timestamp":1785143091754,"version":"3.55.0"},"reference-count":41,"publisher":"American Chemical Society (ACS)","issue":"11","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Suppression of immune checkpoint pathways enables tumor cells to take over immunoregulatory functions, promoting cell growth and proliferation. Elevated adenosine production in the tumor microenvironment suppresses immune checkpoint control through activation of A2A adenosine receptors on immune cells. While A2A antagonists originally developed for CNS indications have entered oncology, their potency may be insufficient to challenge locally high adenosine concentrations within the tumor microenvironment for receptor occupancy. Here, we describe the discovery of INCB106385 (36), a potent dual A2A\/A2B antagonist identified from in-house screening efforts. Compound 36 exhibits high potency at both receptors, favorable drug-like properties, and limited CNS penetration. In preclinical studies, it demonstrated robust pharmacokinetics across species and significant efficacy in a multiday CT26 mouse colon carcinoma model. These findings supported the advancement of INCB106385 into Phase 1 clinical trials (NCT04580485, NCT04989387) for cancer immunotherapy.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c00964","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:50:33Z","timestamp":1779893433000},"page":"13899-13918","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of\nDual A2A\/A2B Adenosine\nReceptor Antagonist and Clinical Candidate INCB106385"],"prefix":"10.1021","volume":"69","author":[{"given":"Chao","family":"Qi","sequence":"first","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9961-2796","authenticated-orcid":true,"given":"Matthew S.","family":"McCammant","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Yu","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Carlsen","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heeoon","family":"Han","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Zhao","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Gan","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingquan","family":"Qian","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia","family":"Hoang","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhong","family":"He","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Mei","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Harris","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Gallion","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hansbury","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Mason","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Stump","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri","family":"Kurzeja-Lipinski","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"DiRamio","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryanne","family":"Covington","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Koblish","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Diamond","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Scherle","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Yao","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Incyte Corporation , , , ,","place":["Wilmington, Delaware, United States, 19803"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"1","key":"2026072621081467000_cit1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology Meets Immunology: The Cancer-Immunity Cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"6382","key":"2026072621081467000_cit2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy\nusing checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"4","key":"2026072621081467000_cit3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade\nof immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"25","key":"2026072621081467000_cit4","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response\nRate to PD-1 Inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"2026072621081467000_cit5","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance Mechanisms\nto Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic\nFactors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"2026072621081467000_cit6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","article-title":"Targeting adenosine for cancer immunotherapy","volume":"6","author":"Leone","year":"2018","journal-title":"Immunother. Cancer"},{"key":"2026072621081467000_cit7","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3389\/fimmu.2019.00925","article-title":"Targeting Adenosine\nin Cancer Immunotherapy to Enhance T-Cell Function","volume":"10","author":"Vigano","year":"2019","journal-title":"Front. Immunol."},{"issue":"12","key":"2026072621081467000_cit8","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/nrc3613","article-title":"Immunity,\ninflammation and cancer: a leading role for adenosine","volume":"13","author":"Antonioli","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"2026072621081467000_cit9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coph.2016.04.001","article-title":"Immunosuppressive activities\nof adenosine in cancer","volume":"29","author":"Allard","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"issue":"8","key":"2026072621081467000_cit10","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1007\/s00018-021-03761-6","article-title":"Structure and function of adenosine\nreceptor heteromers","volume":"78","author":"Franco","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"issue":"8","key":"2026072621081467000_cit11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.str.2017.06.012","article-title":"Structures of Human A(1) and A(2A)\nAdenosine Receptors with Xanthines Reveal Determinants of Selectivity","volume":"25","author":"Cheng","year":"2017","journal-title":"Structure"},{"issue":"3","key":"2026072621081467000_cit12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1172\/JCI89455","article-title":"Targeting\nthe adenosine 2A receptor enhances\nchimeric antigen receptor T cell efficacy","volume":"127","author":"Beavis","year":"2017","journal-title":"J.\nClin. Invest."},{"key":"2026072621081467000_cit13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/978-3-540-89615-9_14","article-title":"Adenosine Receptors\nand Cancer","volume-title":"Adenosine Receptors in Health\nand Disease","author":"Fishman","year":"2009"},{"issue":"8","key":"2026072621081467000_cit14","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1158\/2159-8290.CD-14-0341","article-title":"Targeting Cancer-Derived\nAdenosine: New Therapeutic Approaches","volume":"4","author":"Young","year":"2014","journal-title":"Cancer\nDiscovery"},{"issue":"1","key":"2026072621081467000_cit15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer\nimmunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol. Cancer"},{"issue":"6","key":"2026072621081467000_cit16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","article-title":"CD39 and CD73\nin immunity and inflammation","volume":"19","author":"Antonioli","year":"2013","journal-title":"Trends Mol. Med."},{"issue":"35","key":"2026072621081467000_cit17","doi-asserted-by":"publisher","first-page":"13132","DOI":"10.1073\/pnas.0605251103","article-title":"A2A adenosine\nreceptor protects tumors from antitumor\nT cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"36","key":"2026072621081467000_cit18","doi-asserted-by":"publisher","first-page":"14711","DOI":"10.1073\/pnas.1308209110","article-title":"Blockade\nof A2A receptors potently suppresses the metastasis\nof CD73+ tumors","volume":"110","author":"Beavis","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"5","key":"2026072621081467000_cit19","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","article-title":"Adenosine Receptor\n2A Blockade Increases the Efficacy of Anti\u2013PD-1 through Enhanced\nAntitumor T-cell Responses","volume":"3","author":"Beavis","year":"2015","journal-title":"Cancer Immunol.\nRes."},{"issue":"6","key":"2026072621081467000_cit20","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00262-011-1155-7","article-title":"Enhancement of tumor\nimmunotherapy by deletion of the\nA2A adenosine receptor","volume":"61","author":"Waickman","year":"2012","journal-title":"Cancer Immunol., Immunother."},{"issue":"4","key":"2026072621081467000_cit21","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1073\/pnas.0908801107","article-title":"Anti-CD73 antibody\ntherapy inhibits breast tumor growth and metastasis","volume":"107","author":"Stagg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"12","key":"2026072621081467000_cit22","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1593\/neo.131748","article-title":"Blockade of\nA2b Adenosine Receptor Reduces Tumor Growth and Immune Suppression\nMediated by Myeloid-Derived Suppressor Cells in a Mouse Model of Melanoma","volume":"15","author":"Iannone","year":"2013","journal-title":"Neoplasia"},{"issue":"3","key":"2026072621081467000_cit23","doi-asserted-by":"publisher","DOI":"10.4161\/onci.27989","article-title":"Targeting the adenosine A2b receptor in the tumor microenvironment\novercomes local immunosuppression by myeloid-derived suppressor cells","volume":"3","author":"Morello","year":"2014","journal-title":"OncoImmunology"},{"key":"2026072621081467000_cit24","doi-asserted-by":"publisher","first-page":"1163585","DOI":"10.3389\/fimmu.2023.1163585","article-title":"The resurgence\nof the Adora2b receptor as an immunotherapeutic\ntarget in pancreatic cancer","volume":"14","author":"Strickland","year":"2023","journal-title":"Front. Immunol."},{"issue":"9","key":"2026072621081467000_cit25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3390\/ph13090237","article-title":"Tumor Immunotherapy\nUsing A(2A) Adenosine Receptor Antagonists","volume":"13","author":"Zhang","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"2026072621081467000_cit26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s12032-023-02033-6","article-title":"Istradefylline induces A2A\/P2 \u00d7\n7 crosstalk expression inducing pro-inflammatory signal, and reduces\nAKT\/mTOR signaling in melanoma-bearing mice","volume":"40","author":"Gutknecht da Silva","year":"2023","journal-title":"Med. Oncol."},{"issue":"2","key":"2026072621081467000_cit27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000417","article-title":"Small molecule AZD4635\ninhibitor of A2AR signaling\nrescues immune cell function including CD103+ dendritic cells enhancing\nanti-tumor immunity","volume":"8","author":"Borodovsky","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"2026072621081467000_cit28","doi-asserted-by":"publisher","first-page":"PR001","DOI":"10.1158\/1538-8514.CANCERCHEM24-PR001","article-title":"Abstract PR001: Discovery of Etrumadenant,\na first-in-class dual A2a and A2b adenosine receptor antagonist for\ncancer immunotherapy","volume":"23","author":"Sharif","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"2026072621081467000_cit29","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1158\/1535-7163.MCT-23-0843","article-title":"Dual A2A\/A2B Adenosine\nReceptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms\nof Adenosine and Reduces Tumor Growth In Vivo","volume":"23","author":"Schiemann","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"2026072621081467000_cit30","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1200\/JCO.2017.35.15_suppl.3004","article-title":"Safety and clinical\nactivity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in\nanti-PD1\/PDL1 treatment-refractory renal cell (RCC) and non-small\ncell lung cancer (NSCLC) patients","volume":"35","author":"Fong","year":"2017","journal-title":"J. Clin.\nOncol."},{"issue":"8","key":"2026072621081467000_cit31","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1161\/01.RES.0000094744.88220.62","article-title":"Activation of Adenosine A1 Receptor Attenuates Cardiac\nHypertrophy and Prevents Heart Failure in Murine Left Ventricular\nPressure-Overload Model","volume":"93","author":"Liao","year":"2003","journal-title":"Circ. Res."},{"key":"2026072621081467000_cit32","unstructured":"Courter, J. R.; Li, J.; Wu, L.; He, C.; Lu, L.; Sun, Y.; Wang, X.; Yao, W.; Zhuo, J.; Zhang, C.\n          Imidazopyrazines\nas LSD1 inhibitors\nand their preparation.WO 2,016,007,736 A1, 2016."},{"issue":"7","key":"2026072621081467000_cit33","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1021\/acs.oprd.0c00124","article-title":"Development of a Scalable and Practical\nSynthesis of AB928, a Dual A2a\/A2b Receptor Antagonist","volume":"24","author":"Sharif","year":"2020","journal-title":"Org. Process Res. Dev."},{"issue":"6","key":"2026072621081467000_cit34","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.1021\/acs.jmedchem.4c00250","article-title":"Subtle Structural Changes across the Boundary\nbetween\nA2AR\/A2BR Dual Antagonism and A2BR Antagonism: A Novel Class of 2-Aminopyrimidine-Based\nDerivatives","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"7","key":"2026072621081467000_cit35","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1021\/acs.jmedchem.2c01860","article-title":"Discovery of Pyridinone\nDerivatives as Potent, Selective, and Orally\nBioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy","volume":"66","author":"Zhu","year":"2023","journal-title":"J. Med. Chem."},{"issue":"9","key":"2026072621081467000_cit36","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1021\/jm4011669","article-title":"Adenosine A2A Receptor\nas a Drug Discovery Target","volume":"57","author":"de Lera Ruiz","year":"2014","journal-title":"J. Med. Chem."},{"issue":"13","key":"2026072621081467000_cit37","first-page":"2602","article-title":"The extracellular\nfluid of solid\ncarcinomas contains immunosuppressive concentrations of adenosine","volume":"57","author":"Blay","year":"1997","journal-title":"Cancer Res."},{"issue":"4","key":"2026072621081467000_cit38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1359-6446(03)02961-1","article-title":"Prediction\nof blood\u2013brain barrier penetration: are we missing the point?","volume":"9","author":"Martin","year":"2004","journal-title":"Drug Discovery Today"},{"issue":"9","key":"2026072621081467000_cit39","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1124\/dmd.105.008201","article-title":"Evaluation\nof cerebrospinal fluid concentration and plasma free concentration\nas a surrogate measurement for brain free concentration","volume":"34","author":"Liu","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"2026072621081467000_cit40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1158\/2326-6066.CIR-16-0114","article-title":"Rational\nSelection of Syngeneic Preclinical Tumor Models for Immunotherapeutic\nDrug Discovery","volume":"5","author":"Mosely","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"2026072621081467000_cit41","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1021\/cc049890v","article-title":"Preparative LC\u2013MS\nPurification: Improved Compound-Specific Method Optimization","volume":"6","author":"Blom","year":"2004","journal-title":"J. Comb. Chem."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c00964","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/11\/13899\/66272870\/acs.jmedchem.6c00964.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/11\/13899\/66272870\/acs.jmedchem.6c00964.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T08:18:44Z","timestamp":1785140324000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/11\/13899\/5201072\/Discovery-of-Dual-A2A-A2B-Adenosine-Receptor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,5,27]]},"published-print":{"date-parts":[[2026,6,11]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c00964","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}